Free Trial

Covalon Technologies (CVE:COV) Shares Down 16.7% - Time to Sell?

Covalon Technologies logo with Medical background

Key Points

  • Covalon Technologies Ltd. shares fell by 16.7%, trading at C$2.40, down from a previous close of C$2.88.
  • The company experienced a substantial increase in trading volume, with 181,028 shares exchanged, marking a surge of 555% compared to the average volume.
  • Covalon specializes in medical products for infection management and wound care, holding a market cap of C$65.76 million and a high debt-to-equity ratio of 3.28.
  • Need better tools to track Covalon Technologies? Try 5 Weeks of MarketBeat All Access for $5. Start Portfolio Tracking Now.

Shares of Covalon Technologies Ltd. (CVE:COV - Get Free Report) traded down 16.7% during mid-day trading on Thursday . The company traded as low as C$2.36 and last traded at C$2.40. 181,028 shares changed hands during mid-day trading, an increase of 555% from the average session volume of 27,638 shares. The stock had previously closed at C$2.88.

Covalon Technologies Stock Down 16.7%

The business has a 50-day simple moving average of C$2.52 and a 200-day simple moving average of C$2.51. The company has a debt-to-equity ratio of 3.28, a quick ratio of 6.45 and a current ratio of 7.27. The company has a market cap of C$65.76 million, a price-to-earnings ratio of 27.55 and a beta of 0.64.

Covalon Technologies Company Profile

(Get Free Report)

Covalon Technologies Ltd. engages in the research, development, manufacturing, and marketing of medical products in infection management, advanced wound care, and surgical procedure areas in the United States, Canada, the Middle East, Asia, Latin America, and internationally. The company's platform technologies comprise collagen matrix platform that is used to manufacture a family of products to treat chronic and infected wounds, including diabetic ulcers, pressure ulcers, venous ulcers, donor and graft sites, traumatic wounds healing by secondary intention, dehisced surgical wounds, and first and second degree burns; and antimicrobial silicone adhesive platform, which is used for family of pre and post-surgical, and vascular access products that are designed to kill bacteria or yeast that comes into contact with the antimicrobial silicone providing broad-spectrum antimicrobial activity.

Further Reading

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Covalon Technologies Right Now?

Before you consider Covalon Technologies, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Covalon Technologies wasn't on the list.

While Covalon Technologies currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The 10 Best AI Stocks to Own in 2025 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Next Tech Boom: AI Robots Are Coming Sooner Than You Think!
Tech Stocks Stumble: Will Nvidia’s Report Spark a Rebound?
Follow the Money: 5 Stocks Institutions Are Buying NOW

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines